Following her attendance at #DIAEurope 2024, pharmaphorum talks to Humaira Qureshi, president of Qinecsa Solutions, about overcoming the historic challenges of #pharmacovigilance (PV) and embracing a new future-ready PV ecosystem.

pharmaphorum.com/rd/embracing-n…

California will start selling its own #generic of overdose reversal agent naloxone in another example of the use of government-level purchasing power to reduce drug prices. #drugpricing

pharmaphorum.com/news/californi…

Every individual is more than their weight — or the number they hope to see on the scale. Consequently, it’s important to design treatment strategies around the #patient as a person and not just their #weightloss goals. #obesity

pharmaphorum.com/patients/our-e…

. Prime Medicine has been given approval by the FDA for the first human trial of its prime editing technology in patients with chronic granulomatous disease. $PRME #GeneEditing

pharmaphorum.com/news/prime-edi…

In another setback for the #pharma industry, a US judge has rejected a bid to overturn the Medicare #drugpricing negotiation brought by @BMSnews and @JNJnews.

pharmaphorum.com/news/bms-jj-ch…

Patients in the US with ultra #raredisease #WHIMsyndrome now have their first FDA-approved treatment, X4 Pharmaceuticals’s Xolremdi, which targets the underlying mechanism behind the disorder.

pharmaphorum.com/news/x4-pharma…

With 15 years of deep experience in #cardiology , Dr Jay Shah applies his expertise in his role as CMO of #Aktiia to ensure the technology and product remain ahead of the field, trusted by both #patients and professionals. #12QuestionsWith

pharmaphorum.com/rd/12-question…

Japan’s Ono #Pharma has bolstered its #oncology pipeline with a $2.4 billion agreement to buy Deciphera Pharma and its #GIST therapy Qinlock. $DCPH

pharmaphorum.com/news/ono-swoop…

Katherine Forbes, director of #innovation and enterprise at Kidney Research UK, discusses the evolving role of #medicalresearchcharities in facilitating collaborative #partnerships & new ways of working to accelerate #research and improve #patientoutcomes

pharmaphorum.com/patients/spotl…

The #healthcare industry is getting hit more and more frequently by #ransomware attacks - pharmaphorum finds this is due to the scale of #patientdata and the need to keep operations running, necessitating new solutions to counter the threat.

pharmaphorum.com/digital/why-he…

With 15 years of deep experience in #cardiology , Dr Jay Shah applies his expertise in his role as CMO of #Aktiia to ensure the technology and product remain ahead of the field, trusted by both #patients and professionals. #12QuestionsWith

pharmaphorum.com/rd/12-question…

On this #podcast , host Jonah Comstock is joined by Dr Amit Etkin, founder and CEO of #AltoNeuroscience , a recently IPO'd #biotech that wants to bring #precisionmedicine to psychiatry. #mentalhealth

pharmaphorum.com/rd/precision-p…

An alliance between Huma and @Merckgroup to develop digital support tools for #cancer patients has borne fruit with the launch of a #bladdercancer app in the UK. #digitalhealth

pharmaphorum.com/news/merck-hum…

George Medicines has appointed former Ironwood CEO Mark Mallon to lead the UK #pharma company as it tries to get its triple therapy for #hypertension over the finish line.

pharmaphorum.com/news/ex-ironwo…

CHMP backs EU approval of @JNJnews’ Rybrevant as a first-line therapy for NSCLC with EGFR exon 30 insertion mutations, filling a void left after Takeda's Exkivity was pulled from sale. #lungcancer #oncology

pharmaphorum.com/news/jj-gets-c…

A brief history of #ADCs , exploring what they can teach us about advancing #cancer treatments, and offering insights into challenges and opportunities that lie ahead for ADCs and #celltherapies .

pharmaphorum.com/rd/emergence-a…

Get the latest in-depth news and analysis on #pharma and #healthcare - subscribe today to pharmaphorum here: bit.ly/3Wkw6dQ

. @Pfizer has said it will launch its just-approved #hemophiliaB #genetherapy Beqvez with a warranty programme that will provide “greater certainty” to payers in the US.

pharmaphorum.com/news/pfizer-of…

Report from Evaluate Pharma shows growth in the #orphandrugs sector is slowing down, in part as #pharma and payers’ attention has refocused on treatments for more widespread conditions, and there may be turbulent times ahead.

pharmaphorum.com/news/pharmas-i…

Following her attendance at #DIAEurope 2024, pharmaphorum talks to Humaira Qureshi, president of Qinecsa Solutions, about overcoming the historic challenges of #pharmacovigilance (PV) and embracing a new future-ready PV ecosystem.

pharmaphorum.com/rd/embracing-n…